Adamas Completes Acquisition of OSMOLEX ERģ

(January 5, 2021) – Adamas completed acquisition of OSMOLEX ER® via a settlement of patent litigation with Osmotica Pharmeceuticals US LLC. OSMOLEX ER® is an FDA-approved, extended-release tablet for the treatment of Parkinson’s disease. Click here to learn more about Adamas and OSMOLEX ER®.